



LUND UNIVERSITY

Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS).

Tajar, Abdelouahid; Huhtaniemi, Ilpo T; O'Neill, Terence W; Finn, Joseph D; Pye, Stephen R; Lee, David M; Bartfai, György; Boonen, Steven; Casanueva, Felipe F F; Forti, Gianni; Giwercman, Aleksander; Han, Thang S; Kula, Krzysztof; Labrie, Fernand; Lean, Michael E J; Pendleton, Neil; Punab, Margus; Vanderschueren, Dirk; Wu, Frederick C W

Published in:

The Journal of clinical endocrinology and metabolism

DOI:

[10.1210/jc.2011-2513](https://doi.org/10.1210/jc.2011-2513)

2012

[Link to publication](#)

Citation for published version (APA):

Tajar, A., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Bartfai, G., Boonen, S., Casanueva, F. F. F., Forti, G., Giwercman, A., Han, T. S., Kula, K., Labrie, F., Lean, M. E. J., Pendleton, N., Punab, M., Vanderschueren, D., & Wu, F. C. W. (2012). Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). *The Journal of clinical endocrinology and metabolism*, 97(5), 1508-1516. <https://doi.org/10.1210/jc.2011-2513>

Total number of authors:

19

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS)

Abdelouahid Tajar, Ilpo T. Huhtaniemi, Terence W. O'Neill, Joseph D. Finn, Stephen R. Pye, David M. Lee, György Bartfai, Steven Boonen, Felipe F. F. Casanueva, Gianni Forti, Aleksander Giwercman, Thang S. Han, Krzysztof Kula, Fernand Labrie, Michael E. J. Lean, Neil Pendleton, Margus Punab, Dirk Vanderschueren, Frederick C. W. Wu, and the EMAS Group

Context: Late-onset hypogonadism (LOH) has been defined as a syndrome in middle-aged and elderly men reporting symptoms in the presence of low testosterone (T).

Objective: The objective of the study was to seek objective biochemical and end-organ evidence of androgen deficiency in men classified as having LOH according to our previously published criteria.

Design, Setting, and Participants: The design of the study included cross-sectional data from the European Male Aging Study on 2966 community-dwelling men aged 40–79 years in eight European countries.

Main Outcome Measure(s): Waist circumference, body mass index, muscle mass, estimated heel bone mineral density (eBMD), hemoglobin, insulin sensitivity, physical activity, metabolic syndrome, insulin resistance index, and cardiovascular disease were measured.

Results: Sixty-three men (2.1%) were classified as having LOH: 36 moderate and 27 severe. They were older and more obese than eugonadal men and had, in proportion to the graded T deficiency, lower muscle mass, eBMD, and hemoglobin, with poorer general health. Both moderate and severe LOH was associated with lower hemoglobin, mid-upper arm circumference, eBMD, physical function (measured by the Short Form-36 questionnaire), slower gait speed and poorer general health. Only men with severe LOH showed significant associations with larger waist circumference ($\beta = 1.93\text{cm}; 0.04\text{--}3.81$), insulin resistance ($\beta = 2.81; 1.39\text{--}4.23$), and the metabolic syndrome (odds ratio 9.94; 2.73–36.22) after adjustments for confounders. Men with low testosterone only (irrespective of symptoms) showed lesser magnitudes of association with the same end points.

Conclusions: LOH is associated with multiple end-organ deficits compatible with androgen deficiency. These data support the existence of a syndrome of LOH in only a minority of aging men, especially those with T below 8 nmol/liter. (*J Clin Endocrinol Metab* 97: 1508–1516, 2012)

The clinical significance of the age-related decline in testosterone (T) (1, 2) in men continues to attract much attention and debate (3). Recent guidelines have attempted to establish a syndrome of late-onset hypogonadism (LOH) as a clinical and biochemical state with advancing age, characterized by typical symptoms and low serum T (4). However, the concept of hypogonadism of aging remains controversial

(3, 5) in the absence of objective evidence of T deficiency in symptomatic older men (6, 7).

We have recently proposed the minimum criteria for the identification of LOH, which entailed the presence of three sexual symptoms (decreased sexual interest and morning erections and erectile dysfunction) in combination with total T below 11 nmol/liter and free T below 220

pmol/liter (8). Nevertheless, putative symptoms of hypogonadism in aging men are highly nonspecific (8). Although we underscored the higher specificity conferred by three sexual symptoms with the lower total T threshold of less than 8.0 nmol/liter, the nature and extent of T deficiency in symptomatic aging men remain uncertain (9, 10). Hypogonadism is a state of androgen deficiency that has an adverse impact on functions of multiple organ systems and quality of life. In addition to reported symptoms, objective manifestations of hypogonadism may include decreased muscle mass and strength, increased body fat, decreased bone mineral density (BMD), and lower hemoglobin (11).

The aim of this study was to seek objective evidence of androgen deficiency based on pertinent biochemical, end-organ, disease state, and quality-of-life alterations in middle-aged and elderly men classified as having LOH according to the criteria previously defined in a general population study (8). In addition, we examined whether the observed associations could be explained by other factors that vary concurrently with gonadal status.

Materials and Methods

Subjects and study design

An age-stratified probability sample of 3369 men aged 40–79 (mean \pm SD 60 \pm 11) yr were recruited from population registers in eight European centers (Florence, Italy; Leuven, Belgium; Malmö, Sweden; Manchester, UK; Santiago de Compostela, Spain; Łódź, Poland; Szeged, Hungary; Tartu, Estonia). After completing a postal health questionnaire, subjects attended the research clinics for further assessments as previously described (vide infra) (12). Ethical approval for the study was obtained in accordance with local institutional requirements in each center, and written informed consent was obtained from each participant.

Assessments

Participants completed an interviewer-assisted questionnaire including the Short Form-36 (SF-36) health survey and a European Male Aging Study (EMAS) sexual function questionnaire (EMAS-SFQ) as previously described (12). Physical function assessments included reported levels of activity by the Physical Activity Scale for the Elderly (PASE) (13) and gait speed in a timed 50-ft walk (14). BMD at the heel was estimated by the

Sahara Sonometer (Hologic, Bedford, MA) from the machine outputs broadband ultrasound attenuation and speed of sound using the equation: estimated heel bone mineral density (eBMD) = $0.002592 \times (\text{broadband ultrasound attenuation} + \text{speed of sound}) - 3.687$ (15). Mid-upper arm muscle circumference (MUAC) – $\pi \times$ triceps skinfold was used as an indicator of lean body mass (16). Body mass index (BMI) was calculated as body weight (kilograms) divided by the square of height (meters).

Hormones, biochemistry, and hematology

A single fasting morning (before 1000 h) venous blood sample was obtained from each subject. Measurement of T and estradiol (E2) were carried out by gas chromatography-mass spectrometry as described previously (17). The lower limit of quantitation was 0.17 nmol/liter for T and 7.34 pmol/liter for E2. The coefficients of variation of T measurements were 2.9% within runs and 3.4% between runs and for E2 3.5% within runs and 3.7% between runs. SHBG, LH, and FSH were measured by the Modular E170 platform electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Free T levels were derived from total hormone, SHBG, and albumin concentrations as previously described (18).

Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, hemoglobin, and glucose were measured in a fasting venous blood sample using standard methods as described elsewhere (19). Insulin was assayed using chemiluminescence. Insulin resistance was calculated using the homeostatic model (HOMA-IR) (20).

Statistical analysis

LOH was defined as the presence of three sexual symptoms (decreased frequency of morning erections and sexual thoughts and erectile dysfunction) in combination with total T less than 11 nmol/liter and free T less than 220 pmol/liter (8). LOH was further divided into two subgroups: moderate = total T of 8 nmol/liter or greater and less than 11 nmol/liter and free T less than 220 pmol/liter and severe = total T less than 8 nmol/liter and free T less than 220 pmol/liter. Men without LOH were considered as eugonadal.

Smoking status was categorized as current *vs.* never and ex-smokers. Comorbidity was classified as none, one, and two or more reported morbid conditions. Poor health was defined as subjects who rated their general health as fair or poor in the SF-36 questionnaire. The metabolic syndrome was defined using the Adult Treatment Panel III guidelines (21) as having at least three of the following risk factors: waist circumference 102 cm or greater, triglyceride level of 1.7 mmol/liter or greater, a HDL cholesterol level less than 1.03 mmol/liter, systolic blood pressure of 130 mm Hg or greater and/or a diastolic blood pressure of 85 mm Hg or greater, and a fasting glucose of 5.6 mmol/liter or greater.

Arthritis Research U.K. Epidemiology Unit (A.T., T.W.O., S.R.P., D.M.L.), Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PT, United Kingdom; Department of Surgery and Cancer (I.T.H.), Imperial College London, Hammersmith Campus, London W12 0NN, United Kingdom; Andrology Research Unit (J.D.F., F.C.W.W.), Developmental and Regenerative Biomedicine Research Group, The University of Manchester, Manchester Academic Health Science Centre, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom; Department of Obstetrics, Gynaecology, and Andrology (G.B.), Albert Szent-Györgyi Medical University, Szeged, Hungary; Department of Geriatric Medicine (S.B.), Katholieke Universiteit Leuven, B-3001 Leuven, Belgium; Department of Medicine (F.F.F.C.), Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago, and Centro de Investigación Biomédica en Red de Fisiopatología Obesidad y Nutrición (CB06/03), Instituto Salud Carlos III, 15705 Santiago de Compostela, Spain; Endocrinology Unit (G.F.), Department of Clinical Physiopathology, University of Florence, 50121 Florence, Italy; Reproductive Medicine Centre (A.G.), Skåne University Hospital, University of Lund, SE-22 184 Lund, Sweden; Department of Endocrinology (T.S.H.), University College London, London W1T 3AA, United Kingdom; Department of Andrology and Reproductive Endocrinology (K.K.), Medical University of Łódź, 90-131 Łódź, Poland; Laboratory of Molecular Endocrinology and Oncology (F.L.), Laval University, Québec City, Canada G1K 7P4; Department of Human Nutrition (M.E.J.L.), University of Glasgow, G12 8TA Glasgow, Scotland, United Kingdom; School of Community-Based Medicine (N.P.), The University of Manchester, Salford Royal National Health Service Trust, Salford M6 8HD, United Kingdom; Andrology Unit (M.P.), United Laboratories of Tartu University Clinics, 50090 Tartu, Estonia; and Department of Andrology and Endocrinology (D.V.), Katholieke Universiteit Leuven, B-3001 Leuven, Belgium

ANOVA and χ^2 tests were respectively used to determine whether there were differences between the LOH (moderate and severe) and eugonadal groups for anthropometrics, hormones, hemoglobin, BMD, and other continuous and categorical variables.

Linear and logistic regression models (unadjusted and adjusted) were used to assess the association between LOH status (independent variable) with various continuous and binary outcome variables respectively, with the eugonadal group as reference category. The analyses were repeated using just the T thresholds of 8–11 nmol/liter and less than 8 nmol/liter irrespective of sexual symptoms with the eugonadal group as the reference category.

Multiple (linear or logistic) regression analyses were performed with serial adjustment for age, BMI, smoking status, and

morbid conditions where appropriate. Results from linear regression models were presented as β -coefficients and 95% confidence intervals (CI) and from logistic regression models as odds ratios (OR) and 95% CI. All statistical analyses were conducted using Intercooled STATA version 9.2 (StataCorp, College Station, TX).

Results

From the initial probability sample of 3369 participants, 150 were excluded because of known pituitary, testicular, or adrenal diseases or current use of medications affecting pituitary/testicular functions or clearance of sex steroids.

TABLE 1. Subject characteristics: analysis sample and by gonadal status

	All (n = 2966)	Eugonadal (n = 2903)	LOH (moderate) (n = 36)	LOH (severe) (n = 27) [Mean (sd)]	P value
Physiological measures					
Study age (yr)	59.15 (10.82)	58.92 (10.77)	71.08 (6.58)	68.39 (7.30)	<0.001
Systolic blood pressure (mmHg)	145.83 (20.70)	145.56 (20.59)	158.06 (23.93)	158.07 (20.68)	<0.001
Diastolic blood pressure (mmHg)	87.35 (12.32)	87.29 (12.32)	89.78 (11.68)	90.41 (13.55)	0.209
Body size and composition					
Body mass index (kg/m ²)	27.64 (4.10)	27.55 (4.02)	30.68 (5.05)	33.15 (6.17)	<0.001
Waist circumference (cm)	98.32 (11.08)	98.07 (10.91)	106.23 (11.47)	114.63 (13.04)	<0.001
MUAC (cm)	27.74 (2.69)	27.74 (2.70)	27.69 (2.14)	28.41 (2.93)	0.436
eBMD (g/cm ²)	0.54 (0.14)	0.55 (0.14)	0.50 (0.11)	0.47 (0.14)	0.002
Hormones					
Total T (nmol/liter)	16.60 (5.91)	16.78 (5.83)	9.63 (0.79)	5.90 (2.02)	<0.001
Free T (pmol/liter)	294.26 (86.64)	297.21 (84.92)	181.65 (24.08)	127.08 (52.34)	<0.001
LH (U/liter)	6.06 (4.17)	6.01 (3.96)	7.78 (6.19)	10.07 (12.81)	<0.001
FSH (U/liter)	8.33 (8.50)	8.19 (8.31)	12.75 (11.63)	16.91 (15.50)	<0.001
SHBG (nmol/liter)	42.35 (19.28)	42.53 (19.31)	35.33 (10.93)	31.86 (20.14)	0.001
E2 (pmol/liter)	74.03 (24.72)	74.36 (24.75)	63.15 (16.13)	51.98 (16.19)	<0.001
Biochemistry					
Total cholesterol (mmol/liter)	5.56 (1.05)	5.57 (1.05)	5.48 (1.03)	5.08 (1.34)	0.049
LDL cholesterol (mmol/liter)	3.47 (0.91)	3.47 (0.91)	3.24 (0.89)	3.04 (1.08)	0.016
HDL cholesterol (mmol/liter)	1.41 (0.37)	1.41 (0.37)	1.38 (0.42)	1.20 (0.38)	0.012
Triglycerides (mmol/liter)	1.45 (0.74)	1.44 (0.74)	1.66 (0.85)	1.84 (0.64)	0.005
Glucose (mmol/liter)	5.62 (1.33)	5.60 (1.29)	5.89 (2.17)	7.09 (2.44)	<0.001
Insulin (μ U/ml)	11.98 (10.84)	11.85 (10.73)	14.17 (10.25)	22.75 (16.18)	<0.001
HOMA-IR	3.18 (3.93)	3.13 (3.86)	3.70 (3.17)	7.84 (7.67)	<0.001
Hematology					
Hemoglobin (g/liter)	14.98 (1.09)	15.00 (1.08)	14.41 (1.10)	13.96 (1.57)	<0.001
Quality of life					
SF-36 physical function	50.28 (8.05)	50.46 (7.93)	41.87 (9.43)	41.71 (8.38)	<0.001
SF-36 mental function	51.76 (9.17)	51.80 (9.10)	49.71 (11.35)	50.19 (13.31)	0.286
Physical activity/cognition					
PASE score	200.26 (91.22)	201.33 (91.03)	155.99 (88.42)	144.34 (86.19)	<0.001
15-ft walk gait speed (sec)	13.45 (3.27)	13.39 (3.21)	15.98 (4.89)	16.68 (4.07)	<0.001
Digit symbol substitution	28.11 (8.71)	28.22 (8.69)	21.60 (8.18)	24.31 (7.40)	<0.001
Health status					
			Count (%)		
General health (fair or poor)	750 (25.39)	711 (24.59)	22 (61.11)	17 (65.38)	<0.001
2 or more morbid conditions	637 (21.81)	604 (21.13)	19 (52.78)	14 (53.85)	<0.001
CVD	1,034 (34.86)	990 (34.10)	27 (75.00)	17 (62.96)	<0.001
Diabetes	204 (6.98)	191 (6.68)	5 (13.89)	8 (30.77)	<0.001
Metabolic syndrome	668 (22.74)	629 (21.87)	17 (47.22)	22 (84.62)	<0.001

Values in first four columns are expressed as mean (sd).

P value: ANOVA for continuous variables (tests whether or not the means of the three groups are all equal) and χ^2 for categorical variables (a test of independence). Extremely high levels of total cholesterol, LDL cholesterol, hemoglobin (levels > 40), and triglycerides (levels > 4.29) were excluded from the analyses. CVD, Cardiovascular disease.

Complete data on T and sexual symptoms were available among 2966 men. Table 1 shows the baseline characteristics of the entire analysis cohort and after subdivision by gonadal status (eugonadal, moderate LOH, and severe LOH).

There were 63 men with LOH, *i.e.* with three sexual symptoms and low T (2.1% of the 2966 men). Among them, 36 (1.2%) had total T between 8 and 11 nmol/liter and free T less than 220 pmol/liter (moderate LOH), and

27 (0.9%) had total T levels below 8 nmol/liter and free T less than 220 pmol/liter (severe LOH). LH and FSH were higher than in eugonadal men in both LOH groups, and SHBG and E2 levels were lower in the severe LOH group (Table 1).

Compared with eugonadal men, both LOH groups were older and had higher BMI and waist circumference and lower eBMD (Table 1). They also had lower hemoglobin lower HDL cholesterol, higher triglycerides, and

TABLE 2. Relationship between gonadal status and candidate attributes of androgen deficiency: linear regression

Model	Model I: unadjusted	Model II: adjusted for age [β-Coefficient (95% CI)]	Model III: adjusted for age and BMI	Model IV: adjusted for age, BMI, smoking status, and comorbidity
Primary end points				
Hemoglobin (g/liter)				
Moderate	-0.58 (-0.94, -0.23) ^b	-0.42 (-0.77, -0.06) ^a	-0.48 (-0.84, -0.12) ^b	-0.46 (-0.82, -0.11) ^a
Severe	-1.04 (-1.45, -0.62) ^c	-0.91 (-1.32, -0.50) ^c	-1.02 (-1.43, -0.61) ^c	-1.06 (-1.48, -0.64) ^c
MUAC (cm)				
Moderate	-0.05 (-0.93, 0.84)	0.62 (-0.25, 1.49)	-0.71 (-1.36, -0.07) ^a	-0.71 (-1.36, -0.06) ^a
Severe	0.67 (-0.35, 1.69)	1.19 (0.19, 2.19) ^a	-1.22 (-1.97, -0.48) ^b	-1.24 (-2.01, -0.48) ^b
eBMD (g/cm ²)				
Moderate	-0.05 (-0.09, -0.005) ^a	-0.04 (-0.08, 0.01)	-0.05 (-0.09, -0.002) ^a	-0.05 (-0.09, -0.002) ^a
Severe	-0.07 (-0.13, -0.02) ^b	-0.06 (-0.12, -0.01) ^a	-0.09 (-0.14, -0.03) ^b	-0.09 (-0.14, -0.04) ^b
Waist circumference (cm)				
Moderate	8.16 (4.56, 11.752) ^c	6.63 (3.03, 10.225) ^c	-0.67 (-2.28, 0.939)	-0.76 (-2.37, 0.838)
Severe	16.56 (12.41, 20.70) ^c	15.37 (11.24, 19.50) ^c	2.13 (0.28, 3.99) ^a	1.93 (0.04, 3.81) ^a
Secondary end points				
Glucose (mmol/liter)				
Moderate	0.28 (-0.15, 0.72)	0.11 (-0.32, 0.55)	-0.07 (-0.50, 0.35)	-0.13 (-0.56, 0.30)
Severe	1.49 (0.99, 1.99) ^c	1.36 (0.86, 1.86) ^c	1.01 (0.52, 1.51) ^c	1.06 (0.56, 1.57) ^c
Insulin (μIU/ml)				
Moderate	2.32 (-1.22, 5.87)	2.23 (-1.34, 5.81)	-0.96 (-4.23, 2.31)	-1.22 (-4.51, 2.07)
Severe	10.90 (6.81, 14.99) ^c	10.83 (6.72, 14.93) ^c	5.00 (1.23, 8.78) ^b	4.88 (1.01, 8.74) ^a
HOMA-IR				
Moderate	0.57 (-0.71, 1.85)	0.42 (-0.88, 1.71)	-0.58 (-1.78, 0.63)	-0.69 (-1.90, 0.52)
Severe	4.71 (3.23, 6.19) ^c	4.59 (3.10, 6.07) ^c	2.76 (1.38, 4.15) ^c	2.81 (1.39, 4.23) ^c
Total cholesterol (mmol/liter)				
Moderate	-0.09 (-0.44, 0.25)	-0.004 (-0.35, 0.34)	0.03 (-0.32, 0.38)	0.06 (-0.28, 0.41)
Severe	-0.49 (-0.89, -0.09) ^a	-0.42 (-0.82, -0.02) ^a	-0.36 (-0.76, 0.04)	-0.32 (-0.73, 0.08)
LDL cholesterol (mmol/liter)				
Moderate	-0.24 (-0.55, 0.07)	-0.18 (-0.49, 0.13)	-0.14 (-0.46, 0.17)	-0.11 (-0.42, 0.19)
Severe	-0.43 (-0.78, -0.09) ^a	-0.39 (-0.74, -0.04) ^a	-0.33 (-0.68, 0.02)	-0.28 (-0.63, 0.07)
HDL cholesterol (mmol/liter)				
Moderate	-0.03 (-0.15, 0.09)	-0.05 (-0.17, 0.07)	0.03 (-0.09, 0.15)	0.03 (-0.08, 0.15)
Severe	-0.21 (-0.35, -0.07) ^b	-0.22 (-0.36, -0.08) ^b	-0.09 (-0.22, 0.05)	-0.11 (-0.25, 0.03)
Triglycerides (mmol/liter)				
Moderate	0.22 (-0.03, 0.47)	0.29 (0.04, 0.54) ^a	0.16 (-0.09, 0.40)	0.14 (-0.10, 0.39)
Severe	0.40 (0.12, 0.68) ^b	0.45 (0.17, 0.73) ^b	0.20 (-0.08, 0.47)	0.21 (-0.07, 0.49)
Systolic blood pressure (mm Hg)				
Moderate	12.49 (5.71, 19.28) ^c	6.04 (-0.53, 12.61)	2.78 (-3.66, 9.22)	2.69 (-3.74, 9.13)
Severe	12.51 (4.69, 20.33) ^b	7.49 (-0.06, 15.03)	1.57 (-5.85, 9.00)	2.32 (-5.24, 9.88)
Diastolic blood pressure (mm Hg)				
Moderate	2.49 (-1.56, 6.54)	2.52 (-1.56, 6.60)	0.18 (-3.78, 4.15)	0.25 (-3.71, 4.21)
Severe	3.12 (-1.55, 7.79)	3.14 (-1.55, 7.83)	-1.10 (-5.67, 3.47)	-0.16 (-4.82, 4.49)
SF-36 physical function				
Moderate	-8.59 (-11.28, -5.90) ^c	-6.11 (-8.71, -3.50) ^c	-5.38 (-7.94, -2.81) ^c	-4.79 (-7.24, -2.33) ^c
Severe	-8.75 (-11.82, -5.67) ^c	-6.69 (-9.65, -3.73) ^c	-4.87 (-7.81, -1.93) ^b	-4.11 (-6.97, -1.24) ^b
PASE score				
Moderate	-45.33 (-76.11, -14.55) ^b	-2.91 (-31.13, 25.32)	-2.01 (-30.22, 26.21)	-0.15 (-28.15, 27.86)
Severe	-56.99 (-92.82, -21.16) ^b	-25.57 (-58.29, 7.14)	-23.93 (-56.79, 8.94)	-20.16 (-52.79, 12.47)
50-ft walk gait speed (sec)				
Moderate	2.59 (1.53, 3.66) ^c	1.53 (0.50, 2.56) ^b	1.34 (0.36, 2.33) ^b	1.26 (0.28, 2.24) ^a
Severe	3.30 (2.07, 4.53) ^c	2.47 (1.29, 3.65) ^c	2.13 (0.99, 3.26) ^c	1.90 (0.75, 3.05) ^b

Referent is the eugonadal group. Extremely high levels of total cholesterol, LDL cholesterol, hemoglobin (levels >40), and triglycerides (levels >4.29) were excluded from the analyses.

^a P < 0.05.

^b P < 0.01.

^c P < 0.001.

higher systolic blood pressure. In addition, LOH men had higher levels of glucose, insulin, and HOMA-IR. Physical activity (PASE), gait speed, and physical function (SF-36) were lower in the LOH groups. A higher proportion of men with moderate and severe LOH had diabetes (13.9 and 30.8%, respectively) compared with the eugonadal (6.7%), the metabolic syndrome (47.2 and 84.6 *vs.* 22.7%), and cardiovascular disease (75.0 and 63.0 *vs.* 34.1%) (Table 1).

The relationship between LOH and the various outcomes were further explored (Tables 2 and 3 and Fig. 1A). Both moderate and severe LOH were significantly associated with lower hemoglobin, MUAC, eBMD, and physical function and slower gait speed after adjustment for age, BMI, smoking status and comorbidity, the magnitude of these variations being greater in the severe than moderate group. However, only severe LOH was associated with a larger waist circumference, higher glucose, insulin levels, and HOMA-IR in the fully adjusted models. In men with low T irrespective of sexual symptoms, T of 8–11 nmol/liter (*n* = 247) and less than 8 nmol/liter (*n* = 129) were associated with lower hemoglobin levels and higher glucose, insulin levels, and HOMA-IR (Fig. 1B and Supplemental Table 1, published on The Endocrine Society's Journals Online web site at <http://jcem.endojournals.org>), whereas T less than 8 nmol/liter was also associated with lower MUAC and eBMD. However, the magnitude of these associations with low T was considerably smaller than those observed with LOH (Fig. 1).

In the logistic regression models, both moderate and severe LOH was associated with poorer general health

after adjustment for confounders (Table 3). Severe LOH was also associated with a marked increase in risk of the metabolic syndrome (OR 9.9), mirroring the marked difference in insulin resistance between the two groups. Similarly, a T level of less than 8 nmol/liter, irrespective of sexual symptoms, was associated with the metabolic syndrome, although the magnitude of the effect was considerably smaller (OR 3.0, Supplemental Table 2). A T of 8–11 nmol/liter was associated with only a slight increase in risk of cardiovascular disease (Supplemental Table 2).

Discussion

The present study provides a novel and extensive exploration of biochemical and end organ phenotypic features associated with LOH in a large population of community-dwelling middle-aged and elderly European men.

The relationships between T deficiency and reduced muscle mass, low bone density/osteoporosis, and mild anemia are well recognized (22). These changes in androgen-sensitive target tissues are often sought in clinical practice as corroboratory evidence (tissue markers of androgen deficiency) to support the diagnosis of hypogonadism and to monitor subsequent response to T replacement therapy. The present results demonstrate that a small minority of men from the general population, identified on the basis of sexual symptoms and low T as candidates for LOH, do show variations in multiple tissue sites that are highly compatible with reduced androgen action. The graded and significant associations in three independent

TABLE 3. Relationship between gonadal status and clinical outcomes: logistic regression

	Model I: unadjusted	Model II: adjusted for age	Model III: adjusted for age and BMI	Model IV: adjusted for age, BMI, smoking status, and comorbidity ^a
Odds ratios (95% CI)				
General health (fair or poor)				
Moderate	4.82 (2.45, 9.47) ^d	2.97 (1.49, 5.90) ^c	2.46 (1.22, 4.95) ^b	2.35 (1.14, 4.87) ^b
Severe	5.79 (2.57, 13.06) ^d	3.99 (1.75, 9.10) ^c	2.72 (1.18, 6.27) ^b	3.05 (1.23, 7.54) ^b
Diabetes				
Moderate	2.25 (0.87, 5.86)	1.30 (0.49, 3.43)	0.85 (0.31, 2.32)	0.85 (0.31, 2.34)
Severe	6.21 (2.67, 14.46) ^d	4.26 (1.80, 10.08) ^c	2.25 (0.91, 5.54)	2.26 (0.92, 5.58)
CVD				
Moderate	5.80 (2.72, 12.37) ^d	2.69 (1.23, 5.88) ^b	1.93 (0.85, 4.36)	1.91 (0.85, 4.33)
Severe	3.28 (1.50, 7.20) ^c	1.83 (0.81, 4.12)	0.89 (0.38, 2.07)	0.89 (0.39, 2.07)
Metabolic syndrome				
Moderate	3.20 (1.65, 6.19) ^c	2.65 (1.36, 5.16) ^c	1.04 (0.44, 2.48)	1.06 (0.44, 2.51)
Severe	19.65 (6.75, 57.22) ^d	17.17 (5.88, 50.14) ^d	9.81 (2.70, 35.66) ^c	9.94 (2.73, 36.22) ^c

Referent is the eugonadal group. CVD, Cardiovascular disease.

^a For diabetes and CVD, comorbidity was not included as a covariate in model IV.

^b *P* < 0.05.

^c *P* < 0.01.

^d *P* < 0.001.




FIG. 1. Association between selected end points and LOH (A) and low T (B) (irrespective of symptoms). Values are standardized β -coefficients (per SD) and 95% CI for the difference in mean values of the end point between moderate (□) and severe (■) LOH (A) and T 8–11 nmol/liter (□) and T < 8 nmol/liter (■) (B) compared with the eugonadal group. Results are adjusted for age, BMI, smoking status, and comorbidity.

target tissue responses, *i.e.* hemoglobin, BMD, and lean mass, from eugonadal through moderate to severe hypogonadism provide strong face and construct validity for our proposed criteria to define LOH in aging men. These findings are also externally consistent with the consequences of androgen deprivation therapy (23) for prostate cancer, which induce changes in the same androgen targets (24, 25).

Interestingly, compared with LOH, much smaller effect sizes were observed in the same end points in those with low T irrespective of the presence of sexual symptoms (Fig. 1). This highlights the importance and relevance of sexual symptoms to the identification of LOH with respect to tissue variables compatible with androgen deficiency. By differentiating LOH from simply low T, the presence of the three sexual symptoms serves to confer specificity to the clinical syndrome of LOH. This may improve future clinical management of middle-aged and elderly men with low T.

The magnitude of observed differences (β -coefficient from the fully adjusted models) in hemoglobin (-0.46 and -1.06 g/liter equivalent to a percentage difference of -3.1 and -7.1%) and eBMD (-0.05 and -0.09 g/cm², equivalent to -8.3 and -16%) between LOH (moderate and severe) compared with eugonadal men were similar to those reported in untreated patients with pathological hypogonadism and the subsequent improvement in response to T replacement. Thus, hypogonadal patients showed lower hemoglobin (6% or 0.83 g/liter), which increased after T replacement by 6–8% (26, 27). In older healthy men with short-term experimental GnRH agonist-induced hypogonadism, hemoglobin decreased by 0.36 g/liter or 2.6% (28) in 20 wk. Similarly, heel ultrasound eBMD was reduced by 0.08 g/cm² or 13.4% in prostate cancer patients receiving GnRH agonist androgen-deprivation therapy (29). BMD, as measured by dual energy x-ray absorptiometry, in Klinefelter patients was reduced

by 18 and 27% in the femoral and lumbar regions, respectively (30). T replacement increased BMD by an average of 3.7% in middle-aged men with low T (31). Taken together, these comparisons support the existence of significant androgen deficiency at the tissue level in men considered to have LOH based on clinical and hormonal criteria.

The use of MUAC as a surrogate for lean mass is not widespread in clinical practice [but valid in epidemiological studies (16)]. The lower MUAC was corroborated by the lower physical quality of life and slower gait speed, especially in the severely hypogonadal group, suggesting that both upper and lower limb muscle mass and physical function are reduced in LOH.

Although it is anticipated to find evidence of androgen deficiency in symptomatic men with T less than 8 nmol/liter (mean total T 5.9 nmol/liter in severe LOH), it is noteworthy that even moderate LOH with T between 8 and 11 nmol/liter, regarded as borderline rather than overtly hypogonadal (32), also showed some (albeit weaker) evidence of androgen deficiency at the end-organ level (even after adjustment for age, adiposity, and other potential confounders). This suggests that moderate LOH may not be a transient state with labile T levels. However, it remains unclear whether men with moderate LOH should be candidates for intervention, nor is it apparent which is the optimal treatment modality to correct this moderate T deficiency.

The present results confirm the strong association between low T and obesity (33). This relationship is complex and highly confounded and likely to be bidirectional (34). Obesity can give rise to low T, but hypogonadism can also promote fat accumulation, insulin resistance, and the metabolic syndrome (35). Mechanisms underlying these associations are unclear, but the low or inappropriately normal levels of LH commonly associated with the moderately suppressed T levels observed in obese middle-aged men suggest suppression of hypothalamic-pituitary function in obesity (18, 33). However in the present study, elevated LH and FSH levels were observed in both groups of symptomatic men with low T, suggesting that the predominant primary defect in LOH is testicular dysfunction rather than hypothalamic suppression.

Although we found that LOH men had lower total and LDL cholesterol and higher triglyceride levels in the unadjusted analysis, these differences became nonsignificant after adjustment for BMI. This is in keeping with the lack

of association between LOH and lipid abnormalities after adjustment for BMI. This is in keeping with the lack

of changes in plasma lipids in experimental hypogonadism (36). Because the risk of diabetes and cardiovascular disease was nonsignificant after adjustment for age and BMI in both LOH groups, our data suggest that low T is unlikely to be directly responsible for the apparent association of LOH with these conditions. This is congruent with the current guidelines from U.S. Endocrine Society (4), which does not recommend T therapy in diabetic men with low T. In contrast, the odds ratio for the metabolic syndrome remains inordinately high (OR 9.9), even after full adjustment, in the severe but not moderate LOH group. This reflects the similarly dramatic between-group difference in insulin sensitivity, suggesting that the apparent increased cardiometabolic risks in LOH is mostly explained by obesity and age and is unrelated to T until the level drops below 8 nmol/liter. This clear differentiation in central obesity and insulin sensitivity between the two categories of LOH suggests that there is a threshold T level (of around 8 nmol/liter) below which insulin action becomes impaired (either directly from T deficiency or more likely secondarily to visceral obesity). This finding is supported by two independent pieces of evidence. In dose-response studies of T, in which older (60–75 yr) healthy nonobese men with experimentally induced hypogonadism were replaced with graded doses of T enanthate, fat mass started to increase minimally only at the lowest dose giving a trough T level of 6.1 nmol/liter (28), whereas there was no change in insulin sensitivity (36). Profound T deficiency (<1 nmol/liter) induced by androgen deprivation therapy using GnRH agonists or surgical castration for prostate cancer markedly increased visceral obesity and insulin resistance within 3–6 months (23). Our results are therefore compatible with the bidirectional relationship between T and obesity (18, 23). Thus, although obesity may predispose men to borderline low levels of T, only severe T deficiency (LOH) appears to be associated with visceral fat excess to the extent that increases insulin resistance.

The main strength of our study is the detailed phenotyping of men from a large population-based sample stringently identified to be likely candidates for hypogonadism. Methodological limitations inherent to the EMAS study have been described in detail previously (12). For instance, the data were obtained from a predominantly European population, and results should be extrapolated beyond this setting with care. Also, the cross-sectional nature of the present data constrains making definite causal links between LOH and the explored outcomes. Notwithstanding these reservations, the partition of LOH into moderate and severe categories has revealed significant differences in the T-associated phenotypic features, especially the metabolic end points, which could have clinical implications. In moderate LOH, lipid abnormalities or

insulin resistance may be attributable to obesity rather than gonadal status (*i.e.* low T). Despite some evidence compatible with modest androgen deficiency at the tissue level, our findings would imply that T supplementation for moderate LOH may be unlikely to improve the lipid disturbance, insulin resistance, or glucose homeostasis. In keeping with this, most interventional studies on the effects of T in obese/diabetic men chose an inclusion threshold T level of 11 or 12 nmol/liter (37) and showed only modest effects on insulin action. For this reason, clinical trials of T intervention for LOH with metabolic end points that target men with T less than 8 nmol/liter may show greater effects.

In summary, LOH, as defined by the presence of three sexual symptoms and low T in a small minority of aging men, showed consistent associations with multiple objective features compatible with androgen deficiency: lower hemoglobin, BMD, and lean body mass as well as reduced physical quality of life. These features were more marked in severe than moderate LOH, suggesting a graded relationship with the degree of T deficiency. The same features were less marked in men with low T only, irrespective of symptoms emphasizing the relevance of sexual symptoms in LOH. The present results further highlight the important confounding influence of obesity and age in a number of metabolic and physical function end points frequently found to be abnormal in LOH. These observations impart new insights into the pathophysiology of LOH that could inform the design of future clinical trials and potentially improve current management of symptomatic aging men with low or borderline T.

Acknowledgments

We thank the men who participated in the eight countries, the research/nursing staff in the eight centers: C. Pott (Manchester, UK), E. Wouters (Leuven, Belgium), M. Nilsson (Malmö, Sweden), M. del Mar Fernandez (Santiago de Compostela, Spain), M. Jedrzejowska (Łódź), H.-M. Tabo (Tartu, Estonia), and A. Heredi (Szeged) for their data collection, and C. Moseley (Manchester, UK) for data entry and project coordination. Dr. S. Boonen is senior clinical investigator of the Fund for Scientific Research, Flanders, Belgium (F.W.O.-Vlaanderen); Dr. D. Vanderschueren is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven (Leuven, Belgium). The EMAS Group included the following: Florence, Italy (Gianni Forti, Luisa Petrone, Giovanni Corona); Leuven (Dirk Vanderschueren, Steven Boonen, Herman Borghs); Łódź, Poland (Krzysztof Kula, Jolanta Słowikowska-Hilczler, Renata Walczak-Jedrzejowska); London, United Kingdom (Ilpo Huhtaniemi); Malmö, Sweden (Aleksander Giwercman); Manchester, United Kingdom (Frederick Wu, Alan Silman, Neil Pendleton, Terence O'Neill, Joseph Finn, Philip Steer, Abdel-

ouahid Tajar, David Lee, Stephen Pye); Santiago, Spain (Felipe Casanueva, Mary Lage, Ana I. Castro); Szeged, Hungary (György Bartfai, Imre Földesi, Imre Fejes); Tartu, Estonia (Margus Punab, Paul Korrovitz); and Turku, Finland (Min Jiang).

Address all correspondence and requests for reprints to: Professor Frederick C. W. Wu, Department of Medicine, Manchester Royal Infirmary, Grafton Street, Manchester M13 9WL, United Kingdom. E-mail: frederick.wu@manchester.ac.uk.

The European Male Aging Study is funded by the Commission of the European Communities Fifth Framework Program “Quality of Life and Management of Living Resources” Grant QLK6-CT-2001-00258. Additional support was also provided by Arthritis Research UK and the National Institute for Health Research Manchester Biomedical Research Centre. The principal investigator of the EMAS is Professor Frederick Wu, M.D. (Department of Endocrinology, Manchester Royal Infirmary, Manchester, UK).

Current address for A.T.: Centre for Statistics in Medicine, The University of Oxford, Oxford, United Kingdom.

Disclosure Summary: F.C.W.W. is a consultant for GSK, Bayer-Schering, Jenapharm, Ferring, TAP, Lilly-ICOS, Proctor & Gamble, Ardana Biosciences, Pierre Fabre Medicaments, Acrux DDS Pty. Ltd. and has also chaired advisory board meetings and lectured on their behalf. F.C.W.W. has also received lecture fees from Organon, Bayer-Schering, Lilly-ICOS, Ardana Biosciences, Pierre Fabre Medicaments and has received grant support (2009–2013) from Bayer Schering AG and the New England Research Institute, Watertown, MA. All other authors have nothing to disclose.

References

- Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB 2002 Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *J Clin Endocrinol Metab* 87:589–598
- Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab* 86:724–731
- Wu FC 2007 Commentary: guideline for male testosterone therapy: a European perspective. *J Clin Endocrinol Metab* 92:418–419
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 95:2536–2559
- Snyder PJ 2004 Hypogonadism in elderly men—what to do until the evidence comes. *N Engl J Med* 350:440–442
- Miner MM, Seftel AD 2007 Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? *Int J Clin Pract* 61:622–632
- Liverman CT BD 2004 Testosterone and aging: clinical research directions. Washington, DC: National Academies Press
- Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT 2010 Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med* 363:123–135
- Bhasin S, Wu F 2006 Making a diagnosis of androgen deficiency in adult men: what to do until all the facts are in? *Nat Clin Pract Endocrinol Metab* 2:529
- McKinlay JB, Travison TG, Araujo AB, Kupelian V 2007 Male menopause: time for a decent burial? *Menopause* 14:973–975
- Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC 2009 Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. *J Androl* 30:1–9
- Lee DM, O'Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, Tajar A, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, Wu FC 2009 The European Male Ageing Study (EMAS): design, methods and recruitment. *Int J Androl* 32:11–24
- Washburn RA, Smith KW, Jette AM, Janney CA 1993 The Physical Activity Scale for the Elderly (PASE): development and evaluation. *J Clin Epidemiol* 46:153–162
- Reuben DB, Siu AL 1990 An objective measure of physical function of elderly outpatients. The Physical Performance Test. *J Am Geriatr Soc* 38:1105–1112
- Vanderschueren D, Pye SR, Venken K, Borghs H, Gaytant J, Huhtaniemi IT, Adams JE, Ward KA, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC, O'Neill TW, Boonen S 2010 Gonadal sex steroid status and bone health in middle-aged and elderly European men. *Osteoporos Int* 21:1331–1339
- Landi F, Russo A, Liperoti R, Pahor M, Tosato M, Capoluongo E, Bernabei R, Onder G 2010 Midarm muscle circumference, physical performance and mortality: results from the aging and longevity study in the Sirente geographic area (iSIRENTE study). *Clin Nutr* 29:441–447
- Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J 2006 Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. *J Steroid Biochem Mol Biol* 99:182–188
- Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D 2008 Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. *J Clin Endocrinol Metab* 93:2737–2745
- Lee DM, Rutter MK, O'Neill TW, Boonen S, Vanderschueren D, Bouillon R, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC 2009 Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. *Eur J Endocrinol* 161:947–954
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 112:2735–2752
- Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC 2009 ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *Int J Impot Res* 21:1–8
- Grossmann M, Zajac JD 2011 Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? *Clin Endocrinol (Oxf)* 74:289–293
- Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, Valenti G, Ershler WB, Guralnik JM, Longo DL 2006 Low testos-

- terone levels and the risk of anemia in older men and women. *Arch Intern Med* 166:1380–1388
25. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. *Clin Endocrinol (Oxf)* 74:377–383
 26. Yesilova Z, Ozata M, Oktenli C, Sanisoglu SY, Erbil MK, Dagalp K 2004 Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter's syndrome. *Fertil Steril* 81:1278–1282
 27. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM 1999 Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. *Clin Endocrinol (Oxf)* 51:757–763
 28. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW 2005 Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. *J Clin Endocrinol Metab* 90:678–688
 29. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL 2001 Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. *J Clin Endocrinol Metab* 86:2787–2791
 30. Ferlin A, Schipilliti M, Vinanzi C, Garolla A, Di Mambro A, Selice R, Lenzi A, Foresta C 2011 bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. *J Clin Endocrinol Metab* 96:E739–E45
 31. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A 2005 Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. *Clin Endocrinol (Oxf)* 63:280–293
 32. Kaufman JM, Vermeulen A 2005 The decline of androgen levels in elderly men and its clinical and therapeutic implications. *Endocr Rev* 26:833–876
 33. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC 2010 Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. *J Clin Endocrinol Metab* 95:1810–1818
 34. Laaksonen DE, Niskanen L, Punnonen K, Nyysönen K, Tuomainen TP, Valkonen VP, Salonen JT 2005 The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. *J Clin Endocrinol Metab* 90:712–719
 35. Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic syndrome. *Nat Rev Endocrinol* 5:673–681
 36. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. *J Clin Endocrinol Metab* 87:136–143
 37. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS 2011 Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). *Diabetes Care* 34:828–837



**Save the Date for Endocrine Board Review Course,
September 11-12, 2012, Miami, Florida.**

www.endo-society.org/CEU